SCHEMBL2344162

SCHEMBL2344162

Cc1ccc(C(=O)Nc2ccc(N3CCOCC3)cc2)cc1-c1ccc(C(=O)Nc2ccc(Br)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.63
MAPK1 P28482 2/20 0.63
NPC1 O15118 2/20 0.63
RAB9A P51151 2/20 0.63
TP53 P04637 1/20 0.63
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
MAPT P10636 7/20 0.60
ATM Q13315 1/20 0.60
LMNA P02545 3/20 0.59
MAPK14 Q16539 4/20 0.59
KMT2A Q03164 3/20 0.59
USP2 O75604 1/20 0.59
ALDH1A1 P00352 3/20 0.56
RAF1 P04049 2/20 0.56
BRAF P15056 2/20 0.56
MEN1 O00255 2/20 0.56
RARA P10276 1/20 0.56
RARG P13631 1/20 0.56
GAA P10253 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352480 0.95 PKM (0.70) PKMMAPK1NPC1RAB9ATP53
SCHEMBL2345373 0.91 MAPK14 (0.64) PKMMAPK1NPC1RAB9ATP53
SCHEMBL2344382 0.91 MAPK14 (0.61) PKMMAPK1NPC1RAB9ATP53
SCHEMBL12394214 0.90 NPC1 (0.74) PKMMAPK1NPC1RAB9ATP53
SCHEMBL2353815 0.90 PKM (0.63) PKMMAPK1NPC1RAB9ATP53
SCHEMBL2346560 0.89 RARA (0.66) PKMMAPK1NPC1RAB9ATP53
SCHEMBL2913173 0.89 PKM (0.65) PKMMAPK1NPC1RAB9ATP53
SCHEMBL2342385 0.89 PKM (0.61) PKMMAPK1NPC1RAB9ATP53
SCHEMBL1140770 0.88 NPC1 (0.69) PKMMAPK1NPC1RAB9ATP53
SCHEMBL1140320 0.88 MAPK1 (0.61) PKMMAPK1NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008303-B2 e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin ASTRAZENECA AB (SE) 2011-08-30 US disclosed
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 PKM 4821/4885MAPK1 2782/4885NPC1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.